

Cancerfondens Planeringsgrupp för Radionuklidterapi Göteborg 2019

Wednesday Dec 4 Education

Venue

Program and start of workshop: Wallenberg Conference Center (Medicinaregatan 20A)

End of workshop and Get together: Jubileumsaulan (Gula stråket 2B, at Sahlgrenska University Hospital)

9.30	Registration and coffee	
10.30	Welcome and information	
10.45	Therapy with radiopharmaceuticals - current status and challenges	Eva Forssell-Aronsson
11.15	Dosimetry for radiopharmaceuticals	Katarina Sjögren-Gleisner, Stig Palm
12.00	Lunch	
13.00	Radiolabelling methods – an overview	Emma Aneheim
13.30	Combination therapy with radiopharmaceuticals	Marika Nestor
14.00	Scaffold proteins, promising probes for radionuclide molecular imaging of predictive biomarkers for cancer treatment	Vladimir Tolmachev
14.30	MR for evaluation of treatment response	Mikael Montelius
15.00	Coffee	
15.30	Workshop - introduction	
16.00	”Academic walk” to Jubileumsaulan	
16.30 (ca)	Workshop	
18.00 (ca)	Reports from workshop	
19.00	Get together	

Thursday Dec 5

Venue

Program: Wallenberg Conference Center (Medicinaregatan 20A)

Dinner: Room Birgit Thilander (Medicinaregatan 3)

8.30	Welcome and information	
8.40	Trastuzumab co-treatment improves survival of mice with PC-3 prostate cancer xenografts treated with [177Lu]Lu-DOTAGA-PEG2-RM26 GRPR antagonists	Anna Orlova
9.00	Hsp90 inhibition potentiates ¹⁷⁷ Lu-DOTA-octreotate therapy of neuroendocrine tumours	Tobias Hofving
9.20	Optimizing affibody-mediated PET imaging of HER3 expression using long-lived radiocobalt for the next day PET image	Sara Rimne
9.40	Estimation of long-term risks for cancer induction following adjuvant targeted alpha therapy with curative intent	Erik Leidermark
10.00	Development of designed ankyrin repeat protein (DARPin)-based probes for radionuclide molecular imaging	Anzhelika Vorobyeva
10.20	[68Ga]ABY-028: An albumin binding protein based imaging biomarker for positron emission tomography (PET) studies of albumin transport in altered vascular permeability	Emma Jussing
10.40	Coffee	
11.00	Synthesis and preclinical evaluation of GRPR/PSMA bispecific heterodimers for the theranostics application in prostate cancer	Ayman Abouzayed
11.20	Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumors	Javad Garousi
11.40	Renal radioactivity accumulation in mice injected with radiometal-labeled engineered scaffold proteins affibody molecules and DARPins, is reduced by maleate and fructose	Mohamed Altai
12.00	Årsmöte: Svensk förening för radiobiologi	Lovisa Lundholm
12.30	Lunch	
13.30	¹³¹ I activity quantifications from gamma camera images of thyroid cancer patients	Frida Westerbergh
13.50	The α -emitter Ra-223 induces clustered DNA damage and reduces prostate cancer cell survival independent of ARv7 expression	Bo Stenerlöw
14.10	Commercial presentations	
14.30	Workshop	
15.00	Coffee	
15.30	Workshop	
16.00	Årsmöte: Svensk förening för isotoperapi	Viveka Bergman
19.00	Dinner	

Friday Dec 6

Venue

Program: Wallenberg Conference Center (Medicinaregatan 20A)

9.00	Development of scintigraphy equipment for improved imaging	Cecilia Hindorf, Mattias Sandström
9.40	Cyclotron production of ^{68}Ga using enriched ^{68}Zn foils	Jonathan Siikanen
10.00	Improved dosimetry for optimizing intraperitoneal targeted alpha therapy with ^{211}At	Stig Palm
10.20	Comparative evaluation of tumour-targeting properties of an antagonistic bombesin analogue labelled with residualizing (^{111}In -DOTA) and non-residualizing (^{125}I -Tyr) labels	Maryam Oroujeni
10.40	Coffee and Poster walk	
11.30	Impact of ATM and DNA-PK inhibition on gene expression and individual response of human lymphocytes to mixed beams of alpha particles and X-rays	Lovisa Lundholm
11.50	Phase I evaluation of [$^{99\text{m}}\text{Tc}$]-ADAPT6, a novel scaffold protein-based probe for visualization of HER2 expression in breast cancer	Vladimir Tolmachev
12.10	Evaluation of [^{89}Zr]-based labelling methods for in vivo cell tracking with PET	Thuy Tran
12.30	Imaging of EpCAM expression in pancreatic cancer using radiolabelled DARPin Ec1	Anzhelika Vorobyeva
12.50	Closing of the meeting	
13.00	Lunch	